The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
These medicines are essential in preventing RhD immunisation during pregnancy
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Subscribe To Our Newsletter & Stay Updated
